Case Costing of Cancer in Ontario

Overview

Program Leader: Nicole Mittmann, M.Sc., PhD

• Associate Scientist, Clinical Integrative Biology - Trauma, Emergency and Critical Care Program, Sunnybrook Research Institute;
• Executive Director, Health Outcomes and PharmacoEconomic (HOPE) Research Centre, Division of Clinical Pharmacology, Sunnybrook Health Sciences Centre;
• Assistant Professor, Department of Pharmacology, University of Toronto;
• Co-chair, Committee on Economic Analysis (CEA), National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)

While Ontario has a wealth of high quality, comprehensive administrative health data, relatively little work has examined how to apply these costs for economic evaluations. The ability to do so is an important component of technology evaluation, and Ontario is particularly well poised to contribute in this area of research. Consequently, improving the methodological techniques and expertise for economic studies is one of the priority areas identified in the HSR Program consultative process.

This project is looking at the ability of case costing methodology to assess costs throughout the course of the cancer journey for a number of disease sites. The project will also examine costs by stage of disease as well as compare costs in different geographical regions. The use of ‘real world’ economic data in analyses can, for example, improve the quality of new drug submissions for consideration of Ontario Drug Benefit funding and inform policy-makers about the cost consequences associated with new technologies.

HOPE Research Centre